El Instituto de Salud Carlos III utiliza cookies propias y de terceros para el correcto funcionamiento y visualización del sitio web por parte del usuario, así como la recogida de estadísticas. Si continúa navegando, consideramos que acepta su uso. Para más información visite nuestra Política de Cookies.
Ver más información

We protect your health through science

Search Bar

Usa comillas para buscar una secuencia de palabras exacta. Ej: "Proyectos Financiados"

Investigation

Bacterial Taxonomy

Research Lines

Content with Investigacion Neumococos .

Neumococos

Vigilancia epidemiológica de los serotipos y genotipos que causan enfermedad neumocócica invasiva (ENI) en España. Caracterización molecular de factores de virulencia de neumococo. Identificación y caracterización de proteínas de neumococo candidatas a vacuna. Evaluación de mecanismos de evasión de la respuesta inmune en Streptococcus pneumoniae. Impacto de los biofilms bacterianos en la persistencia del tracto respiratorio. Mecanismos de cronicidad de aislados clínicos de neumococo en pacientes con enfermedad pulmonar obstructiva crónica.

Research projects

Content with Investigacion Neumococos .

1: Título del proyecto: Desarrollo de enzibióticos para combatir infecciones en pacientes con fibrosis quística provocadas por los patógenos Pseudomonas aeruginosa y Staphylococcus aureus: CF-TREAT

Referencia: CPP2022-009574 / MPY 375/23

Agencia Financiadora: Agencia Estatal de Investigación. MICINN.

Fecha Inicio:    01/12/2023
Fecha Fin:    30/11/2026
Financiación: 238.938 Euros
Investigadores principales: Roberto Díez Martínez, José E. Yuste Lobo y Pilar García Suárez

 

2: Título del proyecto: Desarrollo de enzibióticos para combatir infecciones humanas producidas por Enterococcus faecium resistente a vancomicina (ANTI‐VRE).
Proyecto CPP2021-009054 financiado por MICIU/AEI /10.13039/501100011033 y por la Unión Europea NextGenerationEU/ PRTR

Investigadores principales: Roberto Díez Martínez, Jose Yuste Lobo y Mirian Domenech

Periodo: 18/11/2022 - 17/11/2025

Cuantía total: 231.455 €

3: Título del proyecto: Mecanismos de virulencia en patógenos respiratorios.
Entidad financiadora: Ministerio de Ciencia e Innovación, Agencia Estatal de Investigación (Convocatoria «Proyectos I+D+I» 2020 - Modalidades «Retos Investigación» y «Generación de Conocimiento»). Referencia: PID2020-119298RB-I00

Investigador principal: Jose Yuste Lobo

Periodo: 01/09/2021 - 30/08/2024

Cuantía total: 121.000 €

4: Título del proyecto: Efectividad de la vacuna antineumocócica conjugada 13-valente frente a la hospitalización por neumonía adquirida en la comunidad en adultos de 60 años o mayores, mediante un estudio de casos y controles modificado. Estudio CIBELES.

Investigadores principales: Jose Yuste Lobo y Ángel Gil de Miguel
Entidad financiadora: PFIZER. Referencia: MVP 249/20
Periodo: 23/02/2021 - 22/02/2025
Cuantía total: 168.000 €

5: Título del proyecto: Evolution of Invasive Pneumococcal Disease in Spain with special focus on the pathogenesis of serotypes 3, 8, 11A, 19A, 22F and 33F. Investigadores principales: Jose Yuste Lobo y Mirian Domenech.
Entidad financiadora: Merck Sharp & Dohme USA. Referencia: MVP 132/21
Período: 16/06/2021 - 15/12/2023
Cuantía total: 157.448€

6: Título del proyecto: Mecanismos de patogenicidad y protección en bacterias Gram-positivas causantes de enfermedad respiratoria y bacteriemia
Investigador principal: Jose Yuste Lobo
Entidad financiadora: MINECO. Referencia: SAF2017-83388-R
Periodo: 31/12/2017 - 30/06/2021
Cuantía total: 145.200 €

7: Título del proyecto: Characterization of susceptibility to cefditoren investigating penicillin resistant clinical isolates of Streptococcus pneumoniae.
Investigadores: Jose Yuste Lobo y Mirian Domenech Lucas
Entidad financiadora: Tedec Meiji Farma, S.A. Referencia: MVP 119/20
Periodo: 11/07/2020 – 10-07-2022
Cuantía total: 76.517 €

8: Título del proyecto: Impact of clinical isolates of serotypes 22F and 33F in the epidemiology and pathogenesis of Streptococcus pneumoniae.
Investigador principal: Jose Yuste Lobo
Entidad financiadora: Merck Sharp & Dohme España, S.A. Referencia: MVE 213/18
Periodo: 10/05/2018 - 30/05/2021
Cuantía total: 157.604 €

Search Bar

Publications

Sort
Category

Lorente, E., E. Barnea, C. Mir, A. Admon, and D. López. 2020. The HLA-DP peptide repertoire from human respiratory syncytial virus is focused on major structural proteins with the exception of the viral polymerase. J Proteomics. 221:103759.

Lorente, E., E. Barnea, C. Mir, A. Admon, and D. López. 2020. The HLA-DP peptide repertoire from human respiratory syncytial virus is focused on major structural proteins with the exception of the viral polymerase. J Proteomics. 221:103759.

PUBMED DOI

Marquez, A., M. Gomez-Fontela, S. Lauzurica, R. Candorcio-Simon, D. Munoz-Martín, M. Morales, M. Ubago, C. Toledo, P. Lauzurica, and C. Molpeceres. 2020. Fluorescence enhanced BA-LIFT for single cell detection and isolation. Biofabrication. 12:025019.

Marquez, A., M. Gomez-Fontela, S. Lauzurica, R. Candorcio-Simon, D. Munoz-Martín, M. Morales, M. Ubago, C. Toledo, P. Lauzurica, and C. Molpeceres. 2020. Fluorescence enhanced BA-LIFT for single cell detection and isolation. Biofabrication. 12:025019.

PUBMED DOI

Lorente, E., M. Marcilla, P. G. de la Sota, A. Quijada-Freire, C. Mir, and D. López. 2021. Acid Stripping after Infection Improves the Detection of Viral HLA Class I Natural Ligands Identified by Mass Spectrometry. Int.J.Mol.Sci. 22.

Lorente, E., M. Marcilla, P. G. de la Sota, A. Quijada-Freire, C. Mir, and D. López. 2021. Acid Stripping after Infection Improves the Detection of Viral HLA Class I Natural Ligands Identified by Mass Spectrometry. Int.J.Mol.Sci. 22.

PUBMED DOI

de la Sota, P. G., E. Lorente, L. Notario, C. Mir, O. Zaragoza, and D. López. 2021. Mitoxantrone Shows In Vitro, but Not In Vivo Antiviral Activity against Human Respiratory Syncytial Virus. Biomedicines. 9.

de la Sota, P. G., E. Lorente, L. Notario, C. Mir, O. Zaragoza, and D. López. 2021. Mitoxantrone Shows In Vitro, but Not In Vivo Antiviral Activity against Human Respiratory Syncytial Virus. Biomedicines. 9.

PUBMED DOI

Predicted Epitope Abundance Supports Vaccine-Induced Cytotoxic Protection Against SARS-CoV-2 Variants of Concern.

Martín-Galiano, A. J., F. Diez-Fuertes, M. J. McConnell, and D. López. 2021. Predicted Epitope Abundance Supports Vaccine-Induced Cytotoxic Protection Against SARS-CoV-2 Variants of Concern. Front Immunol. 12:732693.

PUBMED DOI

Prediction of Conserved HLA Class I and Class II Epitopes from SARS-CoV-2 Licensed Vaccines Supports T-Cell Cross-Protection against SARS-CoV-1.

López, D. 2022. Prediction of Conserved HLA Class I and Class II Epitopes from SARS-CoV-2 Licensed Vaccines Supports T-Cell Cross-Protection against SARS-CoV-1. Biomedicines. 10.

PUBMED DOI

Abundance, Betweenness Centrality, Hydrophobicity, and Isoelectric Points Are Relevant Factors in the Processing of Parental Proteins of the HLA Class II Ligandome.

Lorente, E., A. J. Martín-Galiano, D. M. Kadosh, A. Barriga, J. Garcia-Arriaza, C. Mir, M. Esteban, A. Admon, and D. López. 2022. Abundance, Betweenness Centrality, Hydrophobicity, and Isoelectric Points Are Relevant Factors in the Processing of Parental Proteins of the HLA Class II Ligandome. J.Proteome.Res. 21:164-171.

DOI

Cross-Recognition of SARS-CoV-2 B-Cell Epitopes with Other Betacoronavirus Nucleoproteins

Tajuelo, A., M. López-Siles, V. Mas, P. Perez-Romero, J. M. Aguado, V. Briz, M. J. McConnell, A. J. Martín-Galiano, and D. López. 2022. Cross-Recognition of SARS-CoV-2 B-Cell Epitopes with Other Betacoronavirus Nucleoproteins. Int.J.Mol.Sci. 23.

PUBMED

Predicted HLA Class I and Class II Epitopes From Licensed Vaccines Are Largely Conserved in New SARS-CoV-2 Omicron Variant of Concern.

López, D. 2022. Predicted HLA Class I and Class II Epitopes From Licensed Vaccines Are Largely Conserved in New SARS-CoV-2 Omicron Variant of Concern. Front Immunol. 13:832889.

PUBMED

Immunoinformatics lessons on the current COVID-19 pandemic and future coronavirus zoonoses

López D, García-Peydró M. “Immunoinformatics lessons on the current COVID-19 pandemic and future coronavirus zoonoses”. Frontiers in Immunology 14:1118267 (2023).

PUBMED DOI

Garcia-Arriaza, J., M. Esteban, and D. López. 2021

Garcia-Arriaza, J., M. Esteban, and D. López. 2021. Modified Vaccinia Virus Ankara as a Viral Vector for Vaccine Candidates against Chikungunya Virus. Biomedicines. 9.

PUBMED

Diagnósitico microbiológico y control de la legionelosis

Pelaz Antolín, C., et al., En Procedimientos en Microbiología Clínica, E.C.y.R. Cantón, Editor. 2005, SEIMC. p. 1-72.

PUBMED

Persistence of chlorine‐sensitive Legionella pneumophila in hyperchlorinated installations

García MT, Baladrón B, Gil V, Tarancon ML, Vilasau A, Ibañez A, Elola C, Pelaz C. J Appl Microbiol. 2008;105(3):837-47.

PUBMED DOI

Legionella-Biofilms-Amebas, un problema industrial, de sanidad ambiental y de salud pública

Juana María González-Rubio, Celia Játiva, Almudena Cascajero, Fernando González-Camacho. Infoplagas, nº 112, agosto 2023 pags: 20-24. (Artículo de divulgación).

DOI

Programa de Legionelosis. En Echevarría Mayo JE y Oteo Iglesias J (Editores). Programas de Vigilancia Microbiológica pags: 74-80. Centro Nacional de Microbiología, Madrid: Instituto de Salud Carlos III, 2021.

Bellido B y Pelaez C: Programa de Legionelosis. En Echevarría Mayo JE y Oteo Iglesias J (Editores). Programas de Vigilancia Microbiológica pags: 74-80. Centro Nacional de Microbiología, Madrid: Instituto de Salud Carlos III, 2021.

Fulminant septic shock due to community-acquired pneumonia caused by Legionella pneumophila SG1 Olda OLDA ST1. Case report

de Miguel-Balsa E, Jaimez Navarro E, Cascajero A, González-Camacho F, González-Rubio JM. J Infect Public Health 2024; 17:1047-9.

PUBMED DOI

Characterisation of Legionella Clinical Isolates in Spain from 2012 to 2022

González-Rubio, J.M.; Cascajero, A.; Baladrón, B.; González-Camacho, F. Microorganisms 2024, 12, 1253

PUBMED DOI

Programa de Legionelosis. En Echevarría Mayo JE y Oteo Iglesias J (Editores) Programas de Vigilancia Microbiológica Centro Nacional de Microbiología.

Fernando González-Camacho y Almudena Cascajero. Programa de Legionelosis. En Echevarría Mayo JE y Oteo Iglesias J (Editores) Programas de Vigilancia Microbiológica Centro Nacional de Microbiología. Volumen 2:77-89. 2021-2022 Majadahonda (Madrid); Instituto de Salud Carlos III, Centro Nacional de Microbiología: 2023.

Chikungunya virus infections among travellers returning to Spain, 2008 to 2014

3. Maria Dolores Fernandez Garcia; Mathieu Bangert; Fernando de Ory; Arantxa Potente; Lourdes Hernandez; Fatima Lasala; Laura Herrero; Francisca Molero; Anabel Negredo; Ana Vázquez; Teodora Minguito; Pilar Balfagón; Jesus de la Fuente; Sabino Puente; Eva Ramírez de Arellano; Mar Lago; Miguel Martinez; Joaquim Gascón; Francesca Norman; Rogelio Lopez Velez; Elena Sulleiro; Diana Pou; Nuria Serre; Ricardo Fernández Roblas; Antonio Tenorio; Leticia Franco; Maria Paz Sanchez Seco. Chikungunya virus infections among travellers returning to Spain, 2008 to 2014. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin. 21 - 36, (Sweden): 08/09/2016. ISSN 1560-7917

PUBMED DOI

Legionella feeleii: Ubiquitous Pathogen in the Environment and Causative Agent of Pneumonia

Vaccaro L, Gomes TS, Izquierdo F, Magnet A, Llorens Berzosa S, Ollero D, Salso S, Alhambra A, Gómez C, López Cano M, Pelaz C, Bellido Samaniego B, Del Aguila C, Fenoy S, Hurtado-Marcos C. Front Microbiol. 2021;12:707187.

DOI

Immunogenicity of a third dose with mRNA-vaccines in the ChAdOx1-S/BNT162b2 vaccination regimen against SARS-CoV-2 variants.

García-Pérez J, Borobia AM, Pérez-Olmeda M, Portolés A, Castaño L, Campins-Artí M, Bertrán MJ, Bermejo M, Arribas JR, López A, Ascaso-Del-Rio A, Arana-Arri E, Fuentes Camps I, Vilella A, Cascajero A, García-Morales MT, Castillo de la Osa M, Pérez Ingidua C, Lora D, Jiménez-Santana P, Pino-Rosa S, Gómez de la Cámara A, De La Torre-Tarazona E, Calonge E, Cruces R, Belda-Iniesta C, Alcamí J, Frías J, Carcas AJ, Díez-Fuertes F. iScience. 2024; 27(9):110728

PUBMED DOI

Longer intervals between SARS-CoV-2 infection and mRNA-1273 doses improve the neutralization of different variants of concern

García-Pérez J, Bermejo M, Ramírez-García A, De La Torre-Tarazona HE, Cascajero A, Castillo de la Osa M, Jiménez P, Aparicio Gómez M, Calonge E, Sancho-López A, Payares-Herrera C, Layunta Acero R, Vicente-Izquierdo L, Avendaño-Solá C, Alcamí J, Pérez-Olmeda M, Díez-Fuertes F. J Med Virol. 2023; 95(3):e28679

PUBMED DOI

Maca (Lepidium meyenii Walp.) inhibits HIV-1 infection through the activity of thiadiazole alkaloids in viral integration.

Apaza-Ticona L, Beltrán M, Moraga E, Cossio D, Bermejo P, Guerra JA, Alcamí J, Bedoya LM. J Ethnopharmacol. 2024; 335:118613

PUBMED DOI

Immune response and reactogenicity after immunization with two-doses of an experimental COVID-19 vaccine (CVnCOV) followed by a third-fourth shot with a standard mRNA vaccine (BNT162b2): RescueVacs multicenter cohort study

Ascaso-Del-Rio A, García-Pérez J, Pérez-Olmeda M, Arana-Arri E, Vergara I, Pérez-Ingidua C, Bermejo M, Castillo de la Osa M, Imaz-Ayo N, Riaño Fernández I, Astasio González O, Díez-Fuertes F, Meijide S, Arrizabalaga J, Hernández Gutiérrez L, de la Torre-Tarazona HE, Mariano Lázaro A, Vargas-Castrillón E, Alcamí J, Portolés A; RescueVac study Group. EClinicalMedicine. 2022; 51:101542

PUBMED DOI

Immunogenic dynamics and SARS-CoV-2 variant neutralisation of the heterologous ChAdOx1-S/BNT162b2 vaccination: Secondary analysis of the randomised CombiVacS study

García-Pérez J, González-Pérez M, Castillo de la Osa M, Borobia AM, Castaño L, Bertrán MJ, Campins M, Portolés A, Lora D, Bermejo M, Conde P, Hernández-Gutierrez L, Carcas A, Arana-Arri E, Tortajada M, Fuentes I, Ascaso A, García-Morales MT, Erick de la Torre-Tarazona H, Arribas JR, Imaz-Ayo N, Mellado-Pau E, Agustí A, Pérez-Ingidua C, Gómez de la Cámara A, Ochando J, Belda-Iniesta C, Frías J, Alcamí J, Pérez-Olmeda M; CombiVacS study Group. EClinicalMedicine. 2022; 50:101529

PUBMED DOI

Elite controllers long-term non progressors present improved survival and slower disease progression

Capa L, Ayala-Suárez R, De La Torre Tarazona HE, González-García J, Del Romero J, Alcamí J, Díez-Fuertes F. Sci Rep. 2022; 12(1):16356

PUBMED DOI

Transcriptomic Evidence of the Immune Response Activation in Individuals With Limb Girdle Muscular Dystrophy Dominant 2 (LGMDD2) Contributes to Resistance to HIV-1 Infection

Diez-Fuertes F, López-Huertas MR, García-Pérez J, Calonge E, Bermejo M, Mateos E, Martí P, Muelas N, Vílchez JJ, Coiras M, Alcamí J, Rodríguez-Mora S. Front Cell Dev Biol. 2022; 10:839813

PUBMED DOI

Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial

Borobia AM, Carcas AJ, Pérez-Olmeda M, Castaño L, Bertran MJ, García-Pérez J, Campins M, Portolés A, González-Pérez M, García Morales MT, Arana-Arri E, Aldea M, Díez-Fuertes F, Fuentes I, Ascaso A, Lora D, Imaz-Ayo N, Barón-Mira LE, Agustí A, Pérez-Ingidua C, Gómez de la Cámara A, Arribas JR, Ochando J, Alcamí J, Belda-Iniesta C, Frías J; CombiVacS Study Group. Lancet. 2021; 398(10295):121-130

PUBMED DOI

A Founder Effect Led Early SARS-CoV-2 Transmission in Spain

Díez-Fuertes F, Iglesias-Caballero M, García-Pérez J, Monzón S, Jiménez P, Varona S, Cuesta I, Zaballos Á, Jiménez M, Checa L, Pozo F, Pérez-Olmeda M, Thomson MM, Alcamí J, Casas I. J Virol. 2021; 95(3):e01583-20

PUBMED DOI

Two sporadic cases of Legionellosis associated with the use of domestic ultrasonic humidifiers

Reinares Ortiz, J.; Pérez-Serrano, J.; González-Rubio, J.M.; González-Camacho, F. Microorganisms 2024, 12, 2139.

PUBMED DOI

Broth microdilution protocol for determining antimicrobial susceptibility of Legionella pneumophila to clinically relevant antimicrobials

Sewell M, Farley C, Portal EAR, Lindsay D, Ricci ML, Jarraud S, Scaturro M, Descours G, Krøvel AV, Barton R, Boostom I, Ure R, Kese D, Gaia V, Golob M, Paukner S, Ginevra C, Afshar B, Nadarajah S, Wybo I, Michel C, Echahdi F, González-Rubio JM, González-Camacho F, Mentasti M, Flountzi AS, Petzold M, Moran-Gilad J, Uldum S, Winchell J, Wooton M, Bernard K, Jones LC, Chalker VJ, Spiller OB. J Microbiol Methods. 2025 Jan;228:107071.

PUBMED DOI

Epidemiology, molecular characterisation and antimicrobial susceptibility of Neisseria gonorrhoeae isolates in Madrid, Spain, in 2016

María D. Guerrero-Torres, María B. Menéndez, Carmen S. Guerras, Estela Tello, Juan Ballesteros, Petunia Clavo, Teresa Puerta, Mar Vera, Oskar Ayerdi, Juan C. Carrio, Inmaculada Monzo, Jorge del Romero, Julio A. Vázquez, Raquel Abad. 20. María D. Guerrero-Torres, María B. Menéndez, Carmen S. Guerras, Estela Tello, Juan Ballesteros, Petunia Clavo, Teresa Puerta, Mar Vera, Oskar Ayerdi, Juan C. Carrio, Inmaculada Monzo, Jorge del Romero, Julio A. Vázquez, Raquel Abad. Epidemiol Infect. 2019 Sep 24;147:e274

PUBMED DOI

The global meningitis genome partnership

Rodgers E, Bentley SD, Borrow R, Bratcher HB, Brisse S, Brueggemann AB, Caugant DA, Findlow J, Fox L, Glennie L, Harrison LH, Harrison OB, Heyderman RS, van Rensburg MJ, Jolley KA, Kwambana-Adams B, Ladhani S, LaForce M, Levin M, Lucidarme J, MacAlasdair N, Maclennan J, Maiden MCJ, Maynard-Smith L, Muzzi A, Oster P, Rodrigues CMC, Ronveaux O, Serino L, Smith V, van der Ende A, Vázquez J, Wang X, Yezli S, Stuart JM. J Infect. 2020; 81(4): 510-520

PUBMED DOI

The importance of microbiology reference laboratories and adequate funding for infectious disease surveillance

Shaw D, Torreblanca RA, Amin-Chowdhury Z, Bautista A, Bennett D, Broughton K, Casanova C, Choi EH, Claus H, Corcoran M, Cottrell S, Cunney R, Cuypers L, Dalby T, Davies H, de Gouveia L, Deghmane AE, Desmet S, Domenech M, Drew R, Plessis MD, Duarte C, Fuursted K, Golden A, Almeida SCG, Henares D, Henriques-Normark B, Hilty M, Hoffmann S, Humphreys H, Jacobsson S, Johnson C, Jolley KA, Kawabata A, Kozakova J, Kristinsson KG, Krizova P, Kuch A, Ladhani S, Lâm TT, Ayala MEL, Lindholm L, Litt D, Maiden MCJ, Martin I, Martiny D, Mattheus W, McCarthy ND, Meehan M, Meiring S, Mölling P, Morfeldt E, Morgan J, Mulhall R, Muñoz-Almagro C, Murdoch D, Musilek M, Novakova L, Oftadeh S, Perez-Arguello A, Pérez-Vázquez MD, Perrin M, Prevost B, Roberts M, Rokney A, Ron M, Sanabria OM, Scott KJ, Sempere J, Siira L, de Lemos APS, Sintchenko V, Skoczyńska A, Slotved HC, Smith AJ, Taha MK, Toropainen M, Tzanakaki G, Vainio A, van der Linden MPG, van Sorge NM, Varon E, Moreno JV, Vohrnova S, von Gottberg A, Yuste J, Brueggemann AB. Lancet Digit Health. 2025 Apr;7(4):e275-e281.

PUBMED DOI

Antimicrobial resistance and epidemiological aspects of Neisseria gonorrhoeae in the province of Lleida, Spain (2017-2024).

Cumplido A, Aramburu J, Font M, Montes M, Abad R, López E, Bernet A, Mormeneo S, Prats I, García M, Sánchez E, Bellés A. Enferm Infecc Microbiol Clin (Engl Ed). 2025 Mar;43(3):156-161.

PUBMED DOI

Exploring the sequence diversity and surface expression of Factor H-Binding Protein among invasive serogroup B meningococcal strains from selected European countries

Clark SA, Willerton L, Claus H, Carannante A, Stefanelli P, Abad R, Vázquez JA, Borrow R. Hum Vaccin Immunother. 2024 Dec 31;20(1):2427471

PUBMED DOI

Resultado falso negativo en diversas PCR multiplex y monoplex en un episodio de bacteriemia por Neisseria meningitidis. Implicaciones diagnósticas, terapéuticas y epidemiológicas [False negative result in both multiplex and monoplex PCR in a case of Neisseria meningitidis bacteremia. Diagnostic, therapeutic and epidemiological implications]

Monforte ML, Cebollada R, Escobar MJ, Abad R, Aspiroz C. Rev Esp Quimioter. 2024 Oct;37(5):427-428

PUBMED DOI

Global Meningococcal Initiative: Insights on antibiotic resistance, control strategies and advocacy efforts in Western Europe

Borrow R, Campbell H, Caugant DA, Cherkaoui A, Claus H, Deghmane AE, Dinleyici EC, Harrison LH, Hausdorff WP, Bajanca-Lavado P, Levy C, Mattheus W, Mikula-Pratschke C, Mölling P, Sáfadi MA, Smith V, van Sorge NM, Stefanelli P, Taha MK, Toropainen M, Tzanakaki G, Vázquez J. . J Infect. 2024; 89(6): 106335

PUBMED DOI

Meningococcal disease in the Middle East: A report from the Global Meningococcal Initiative

Al-Abri SS, Abuhasan MY, Albayat SSA, Bai X, Bastaki H, Borrow R, Caugant DA, Dbaibo G, Deghmane AE, Dinleyici EC, Ghuneim N, Sheek-Hussein M, Lucidarme J, Leng S, Koliou MG, Sáfadi MAP, Salman JA, Al-Sanouri T, Smith V, Taha MK, Vázquez J, Wright C, Yezli S. J Infect. 2024; 88(2):71-76.

PUBMED DOI

Antimicrobial-resistant Neisseria gonorrhoeae in Europe in 2020 compared with in 2013 and 2018: a retrospective genomic surveillance study.

Golparian D, Cole MJ, Sánchez-Busó L, Day M, Jacobsson S, Uthayakumaran T, Abad R, Bercot B, Caugant DA, Heuer D, Jansen K, Pleininger S, Stefanelli P, Aanensen DM, Bluemel B, Unemo M; Euro-GASP study group. Lancet Microbe. 2024 May;5(5):e478-e488.

PUBMED DOI

Immunogenicity of the Conjugate Meningococcal ACWY-TT Vaccine in Children and Adolescents Living with HIV

Berzosa A, Guillen S, Epalza C, Escosa L, Navarro ML, Prieto LM, Sainz T, de Ory SJ, Montes M, Abad R, Vázquez JA, García IS, Ramos-Amador JT. Microorganisms. 2023 Dec 23;12(1):30

PUBMED DOI

Outbreak of invasive meningococcal disease caused by a meningococcus serogroup B expressing a rare porA genosubtype (19-54, 15), Spain, March to April 2024.

Abad R, Navarro C, García-Amil C, Montes M, Castañeda-García A, Cuadros JA, Galar A, Martin F, Mena E, Pérez de Madrid S, Román C, Soler M, Vázquez JA. Euro Surveill. 2025 Nov;30(44):2500222

PUBMED DOI

Trends in invasive bacterial diseases during the first 2 years of the COVID-19 pandemic: analyses of prospective surveillance data from 30 countries and territories in the IRIS Consortium

Shaw D, Abad R, Amin-Chowdhury Z, Bautista A, Bennett D, Broughton K, Cao B, Casanova C, Choi EH, Chu YW, Claus H, Coelho J, Corcoran M, Cottrell S, Cunney R, Cuypers L, Dalby T, Davies H, de Gouveia L, Deghmane AE, Demczuk W, Desmet S, Domenech M, Drew R, du Plessis M, Duarte C, Erlendsdóttir H, Fry NK, Fuursted K, Hale T, Henares D, Henriques-Normark B, Hilty M, Hoffmann S, Humphreys H, Ip M, Jacobsson S, Johnson C, Johnston J, Jolley KA, Kawabata A, Kozakova J, Kristinsson KG, Krizova P, Kuch A, Ladhani S, Lâm TT, León ME, Lindholm L, Litt D, Maiden MCJ, Martin I, Martiny D, Mattheus W, McCarthy ND, Meehan M, Meiring S, Mölling P, Morfeldt E, Morgan J, Mulhall R, Muñoz-Almagro C, Murdoch D, Murphy J, Musilek M, Mzabi A, Novakova L, Oftadeh S, Perez-Argüello A, Pérez-Vázquez M, Perrin M, Perry M, Prevost B, Roberts M, Rokney A, Ron M, Sanabria OM, Scott KJ, Sheppard C, Siira L, Sintchenko V, Skoczyńska A, Sloan M, Slotved HC, Smith AJ, Steens A, Taha MK, Toropainen M, Tzanakaki G, Vainio A, van der Linden MPG, van Sorge NM, Varon E, Vohrnova S, von Gottberg A, Yuste J, Zanella R, Zhou F, Brueggemann AB. Lancet Digit Health. 2023 Sep;5(9):e582-e593.

PUBMED DOI

Meningococcal carriage in men who have sex with men presenting at a sexual health unit in Spain

Pérez-González A, Carballo R, Araújo-Ameijeiras A, Abad R, Navarro C, Ocampo A, Poveda E, Potel C. Eur J Clin Microbiol Infect Dis. 2023 Mar;42(3):287-296

PUBMED DOI

Effectiveness of a Meningococcal Group B Vaccine (4CMenB) in Children

Castilla J, García Cenoz M, Abad R, Sánchez-Cambronero L, Lorusso N, Izquierdo C, Cañellas Llabrés S, Roig J, Malvar A, González Carril F, Boone ALD, Pérez Martín J, Rodríguez Recio MJ, Galmés A, Caballero A, García Rojas A, Juanas F, Nieto M, Viloria Raymundo LJ, Martínez Ochoa E, Rivas AI, Castrillejo D, Moreno Pérez D, Martínez A, Borràs E, Sánchez Gómez A, Pastor E, Nartallo V, Arteagoitia JM, Álvarez-Fernández B, García Pina R, Fernández Arribas S, Vanrell J, García Hernández S, Mendoza RM, Méndez M, López-Tercero MM, Fernández-Rodríguez Á, Blanco Á, Carrillo de Albornoz FJ, Ruiz Olivares J, Ruiz-Montero R, Limia A, Navarro-Alonso JA, Vázquez JA, Barricarte A. N Engl J Med. 2023 Feb 2;388(5):427-438

PUBMED DOI

Listeriosis outbreak caused by contaminated stuffed pork, Andalusia, Spain, July to October 2019

Fernández-Martínez NF, Ruiz-Montero R, Briones E, Baños E, García San Miguel Rodríguez-Alarcón L, Chaves JA, Abad R, Varela C; LISMOAN team; Lorusso N. Euro Surveill . 2022 Oct;27(43):2200279

PUBMED DOI

Pertactin-Deficient Bordetella pertussis with Unusual Mechanism of Pertactin Disruption, Spain, 1986-2018

14. Mir-Cros A, Moreno-Mingorance A, Martín-Gómez MT, Abad R, Bloise I, Campins M, González-Praetorius A, Gutiérrez MN, Martín-González H, Muñoz-Almagro C, Orellana MÁ, de Pablos M, Roca-Grande J, Rodrigo C, Rodríguez ME, Uriona S, Vidal MJ, Pumarola T, Larrosa MN, González-López JJ. Emerg Infect Dis. 2022 May;28(5):967-976

PUBMED DOI

Large Increase in Azithromycin-Resistant Neisseria gonorrhoeae in Northern Spain

Carballo R, Povoa MC, Abad R, Navarro C, Martin E, Alvarez M, Salgado A, Potel C. Microb Drug Resist. 2022 Jan;28(1):81-86

PUBMED DOI

High susceptibility to zoliflodacin and conserved target (GyrB) for zoliflodacin among 1209 consecutive clinical Neisseria gonorrhoeae isolates from 25 European countries, 2018.

Unemo M, Ahlstrand J, Sánchez-Busó L, Day M, Aanensen D, Golparian D, Jacobsson S, Cole MJ, Torreblanca RA, Ásmundsdóttir LR, Balla E, De Baetselier I, Bercot B, Carannante A, Caugant D, Borrego MJ, Buder S, Cassar R, Cole M, Dam A, Eder C, Hoffmann S, Hunjak B, Jeverica S, Kirjavainen V, Maikanti-Charalambous P, Miriagou V, Mlynarczyk-Bonikowska B, Pakarna G, Patterson L, Pavlik P, Perrin M, Shepherd J, Stefanelli P, Unemo M, Jelena V, Zákoucká H. J Antimicrob Chemother. 2021 Feb 10:dkab024

PUBMED DOI

Molecular characterization of invasive serogroup B Neisseria meningitidis isolates from Spain during 2015-2018: Evolution of the vaccine antigen factor H binding protein (FHbp)

Abad R, García-Amil C, Navarro C, Martín E, Martín-Díaz A, Vázquez JA. J Infect. 2021 Apr;82(4):37-44

PUBMED DOI

Meningococcal Serogroup B Disease in Vaccinated Children

Soler-Garcia A, Fernández de Sevilla M, Abad R, Esteva C, Alsina L, Vázquez J, Muñoz-Almagro C, Noguera-Julian A. J Pediatric Infect Dis Soc. 2020 Sep 17;9(4):454-459

PUBMED DOI

Distribution of DNA gyrase cleavage sites across the Streptococcus pneumoniae genome: relation to transcription and methylation at GATC sites

Ferrándiz MJ, Hernández P, de la Campa AG. Nucleic Acids Res. 2025; 53(21):gkaf1183.

PUBMED DOI

First Insight into the Genome Sequences of Two Linezolid-Resistant Nocardia farcinica Strains Isolated from Patients with Cystic Fibrosis

2: Valdezate S, Monzón S, Garrido N, Zaballos A, Medina-Pascual MJ, Azcona-Gutiérrez JM, Vilar B, Cuesta I. First Insight into the Genome Sequences of Two Linezolid-Resistant Nocardia farcinica Strains Isolated from Patients with Cystic Fibrosis. Genome Announc. 2017 Nov 16;5(46).

PUBMED DOI

Apoptosis, Toll-like, RIG-I-like and NOD-like Receptors Are Pathways Jointly Induced by Diverse Respiratory Bacterial and Viral Pathogens.

3: Martínez I, Oliveros JC, Cuesta I, de la Barrera J, Ausina V, Casals C, de Lorenzo A, García E, García-Fojeda B, Garmendia J, González-Nicolau M, Lacoma A, Menéndez M, Moranta D, Nieto A, Ortín J, Pérez-González A, Prat C, Ramos-Sevillano E, Regueiro V, Rodriguez-Frandsen A, Solís D, Yuste J, Bengoechea JA, Melero JA. Apoptosis, Toll-like, RIG-I-like and NOD-like Receptors Are Pathways Jointly Induced by Diverse Respiratory Bacterial and Viral Pathogens. Front Microbiol. 2017 Mar 1;8:276

PUBMED DOI

Molecular identification, antifungal resistance and virulence of Cryptococcus neoformans and Cryptococcus deneoformans isolated in Seville, Spain

Gago S, Serrano C, Alastruey-Izquierdo A, Cuesta I, Martín-Mazuelos E, Aller AI, Gómez-López A, Mellado E. Molecular identification, antifungal resistance and virulence of Cryptococcus neoformans and Cryptococcus deneoformans isolated in Seville, Spain. Mycoses. 2017 Jan;60(1):40-50

PUBMED DOI

High-Quality Draft Genome Sequence of Babesia divergens, the Etiological Agent of Cattle and Human Babesiosis

7: Cuesta I, González LM, Estrada K, Grande R, Zaballos A, Lobo CA, Barrera J, Sanchez-Flores A, Montero E. High-Quality Draft Genome Sequence of Babesia divergens, the Etiological Agent of Cattle and Human Babesiosis. Genome Announc. 2014 Nov 13;2(6).

PUBMED DOI

Serum galactomannan-based early detection of invasive aspergillosis in hematology patients receiving effective antimold prophylaxis

8: Duarte RF, Sánchez-Ortega I, Cuesta I, Arnan M, Patiño B, Fernández de Sevilla A, Gudiol C, Ayats J, Cuenca-Estrella M. Serum galactomannan-based early detection of invasive aspergillosis in hematology patients receiving effective antimold prophylaxis. Clin Infect Dis. 2014 Dec 15;59(12):1696-702.

PUBMED DOI

Analysis of the protein domain and domain architecture content in fungi and its application in the search of new antifungal targets.

9: Barrera A, Alastruey-Izquierdo A, Martín MJ, Cuesta I, Vizcaíno JA. Analysis of the protein domain and domain architecture content in fungi and its application in the search of new antifungal targets. PLoS Comput Biol. 2014 Jul 17;10(7):e1003733.

PUBMED DOI

Cryptococcus neoformans can form titan-like cells in vitro in response to multiple signals

2. Trevijano-Contador N, de Oliveira HC, García-Rodas R, Rossi SA, Llorente I, Zaballos Á, Janbon G, Ariño J, Zaragoza Ó. Cryptococcus neoformans can form titan-like cells in vitro in response to multiple signals. PLoS Pathog. 2018 May 18;14(5):e1007007.

PUBMED DOI

Reclassification of the Candida haemulonii complex as Candida haemulonii (C. haemulonii group I), C. duobushaemulonii sp. nov. (C. haemulonii group II), and C. haemulonii var. vulnera var. nov.: three multiresistant human pathogenic yeasts

4. Cendejas-Bueno E, Kolecka A, Alastruey-Izquierdo A, Theelen B, Groenewald M, Kostrzewa M, Cuenca-Estrella M, Gómez-López A, Boekhout T. Reclassification of the Candida haemulonii complex as Candida haemulonii (C. haemulonii group I), C. duobushaemulonii sp. nov. (C. haemulonii group II), and C. haemulonii var. vulnera var. nov.: three multiresistant human pathogenic yeasts. J Clin Microbiol.

PUBMED DOI

Content with Investigacion Neumococos .

List of staff

Additional Information

The research objectives focus on the areas of Bacterial Taxonomy and Microbiology in Public Health:

- Identification of pathogenic bacteria that are difficult to assign taxonomically
- Description of new species
- Study of bacterial population biology through typing
- Epidemiology of antimicrobial resistance and virulence factors for certain bacterial pathogens in different nosocomial/community settings.

These objectives are addressed from the perspective of polyphasic taxonomy (phenotypic and genotypic taxonomy) through the study of targets for genus/species assignment and phylogenetic analyses. The analysis of the virulome and resistome of certain species is approached from the perspective of complete genome sequencing.

Research on invasive infection by Streptococcus pyogenes and other beta-hemolytic streptococci has been carried out since 1994, through the Surveillance Program of the National Center for Microbiology. The typing of invasive S. pyogenes strains circulating in Spain includes determination of: serotype (emm-type); the genetic profile of streptococcal pyrogenic exotoxins; the antimicrobial resistance phenotype; and the genotypes of epidemiologically related strains and/or outbreaks.

The research objectives focus on the areas of Bacterial Taxonomy and Microbiology in Public Health:

- Identification of pathogenic bacteria that are difficult to assign taxonomically
- Description of new species
- Study of bacterial population biology through typing
- Epidemiology of antimicrobial resistance and virulence factors for certain bacterial pathogens in different nosocomial/community settings.

These objectives are addressed from the perspective of polyphasic taxonomy (phenotypic and genotypic taxonomy) through the study of targets for genus/species assignment and phylogenetic analyses. The analysis of the virulome and resistome of certain species is approached from the perspective of complete genome sequencing.

Research on invasive infection by Streptococcus pyogenes and other beta-hemolytic streptococci has been carried out since 1994, through the Surveillance Program of the National Center for Microbiology. The typing of invasive S. pyogenes strains circulating in Spain includes determination of: serotype (emm-type); the genetic profile of streptococcal pyrogenic exotoxins; the antimicrobial resistance phenotype; and the genotypes of epidemiologically related strains and/or outbreaks.

Content with Investigacion Neumococos .